TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9575584

Group type: EXPERIMENTAL
Intervention: Salben (powder for inhalations)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (sodium bensoate)
Number of subjects: 112
Study: 8160726

Group type: EXPERIMENTAL
Intervention: Simultaneous ambulatory monitoring of esophageal pH and motility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflation of an esophageal balloon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter manipulation in the right atrium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation and treatment of chest pain in patients with angiographically normal coronary arteries
Number of subjects: 0
Study: 2975290

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril (all doses)
Number of subjects: 12
Study: 30062393

Group type: EXPERIMENTAL
Intervention: Paravertebral position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shamrock position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medial position
Number of subjects: 30
Study: 28965097

Group type: EXPERIMENTAL
Intervention: Non-selective laryngeal reinnervation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Type I thyroplasty
Number of subjects: 30
Study: 25070400

Group type: EXPERIMENTAL
Intervention: Multifocal additional IOL
Number of subjects: 32
Study: 23645534

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with temozolomide or irinotecan
Number of subjects: 13
Study: 21514988

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 mcg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (20mg vitamin B(6))
Number of subjects: 64
Study: 18068887

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (self-etch adhesive)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond 1 XT (total-etch adhesive)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both adhesives (self-etch and total-etch)
Number of subjects: 50
Study: 17351746

Group type: EXPERIMENTAL
Intervention: 4 mg Afimoxifene gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg Afimoxifene gel
Number of subjects: 0
Study: 14986258

Group type: EXPERIMENTAL
Intervention: Phenotype resistance testing (PT arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype resistance testing (GT arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to either test (VB arm)
Number of subjects: 0
Study: 11258646

Group type: EXPERIMENTAL
Intervention: IAT(3/2) test procedure (3 min step duration, 2 km/h increment until volitional exhaustion)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Retest or alternative test procedures (submaximal, preliminary exercise, 5 min step duration, 1 km/h increment)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Moderate preliminary exercises (approximately 4 mmol/l lactate)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Reduction of speed increment from 2 to 1 km/h
Number of subjects: 111
Study: 9209165

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (JIB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal-weight control subjects
Number of subjects: 8
Study: 7748304

Group type: EXPERIMENTAL
Intervention: Serotonin uptake inhibitors (SUI; e.g., citalopram, fluoxetine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (5‐HT1A receptor partial agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: m‐CPP (5‐HT partial agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron (5‐HT3 antagonist, 0.5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin uptake inhibitors (SUI) with brief psychosocial intervention
Number of subjects: 0
Study: 3433871

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d. for 2 months
Number of subjects: 21
Study: 31816053

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Internet Condition (MIC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nutrition Psychoeducation and Internet Condition (NPC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MIC/NPC (participants achieving clinically meaningful weight loss >2.5%)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MIC/NPC (participants)
Number of subjects: 89
Study: 29535282

Group type: EXPERIMENTAL
Intervention: Active Mandibular Exercise (AME) for 4 weeks, consisting of maximal mouth opening, lateral excursion, and protrusive movement, repeated ten times a day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 26967654

Group type: EXPERIMENTAL
Intervention: Recommendations for trial preparation and conduct, including sensitisation meetings led by local leaders, involvement of Health Extension Workers, and use of local analogies for explaining randomisation.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Delayed intervention arm participants receiving small incentives to continue in the trial.
Number of subjects: 94
Study: 25690416

Group type: EXPERIMENTAL
Intervention: Community workshops promoting gender equity in reproductive health
Number of subjects: 0
Study: 24331681

Group type: EXPERIMENTAL
Intervention: Partial use of formula diet (FD)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Conventional low-caloric diet (CD)
Number of subjects: 229
Study: 19772689

Group type: EXPERIMENTAL
Intervention: Smart Lunch Box intervention
Number of subjects: 1294
Study: 19127781

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (magnet pellets placed at both auricles, acupressure from day 3 to day 6)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 98
Study: 16898002

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) starting at 40 mg/m2, increased to 50 mg/m2 at level 2.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) at dose level 1 (40 mg/m2).
Number of subjects: 9
Study: 12743975

Group type: EXPERIMENTAL
Intervention: Interactive, multimedia CD‐ROM
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional method (self‐study module, brief lecture, demonstration, hands-on experience)
Number of subjects: 77
Study: 10831272

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapeutic agents (IFN‐α and/or IL‐2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 8781467

Group type: EXPERIMENTAL
Intervention: Spermicide-coated condoms
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Any type of condom
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Intercourse frequency
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: History of UTI
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Spermicide-coated condom exposure
Number of subjects: 1233
Study: 1351498

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole
Number of subjects: 100
Study: 6729769

Group type: EXPERIMENTAL
Intervention: Metoprolol + Sulfinpyrazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol + Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone + Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study: 31227528

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG, 1×10^10 colony forming units, twice daily
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Placebo, identical appearing to the probiotic
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2650
Study: 29228205

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1506
Study: 25733009

Group type: EXPERIMENTAL
Intervention: Running subcuticular closure (3-0 monofilament)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vertical mattress closure (2-0 nylon)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Skin staples
Number of subjects: 45
Study: 25185574

Group type: EXPERIMENTAL
Intervention: 30 μg alum‐adjuvanted OspA antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 μg alum‐adjuvanted OspA antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination (6 months or 9 to 12 months after first immunization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 μg and 60 μg OspA antigen
Number of subjects: 0
Study: 22709259

Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 19456845

Group type: EXPERIMENTAL
Intervention: Trucut biopsy (TCB)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Fine needle aspiration with high suction (FNAHS)
Number of subjects: 77
Study: 17913669

Group type: EXPERIMENTAL
Intervention: Rapid‐point 405
Number of subjects: 21000

Group type: EXPERIMENTAL
Intervention: GEM Premier 3000
Number of subjects: 21000

Group type: EXPERIMENTAL
Intervention: i‐STAT 1 (série 300)
Number of subjects: 21000

Group type: EXPERIMENTAL
Intervention: ABL 77
Number of subjects: 21000

Group type: COMPARATOR
Intervention: i‐STAT (série 200)
Number of subjects: 21000

Group type: COMPARATOR
Intervention: OMNI S
Number of subjects: 21000
Study: 16103515

Group type: EXPERIMENTAL
Intervention: Intravenous glucose at 2 mg x kg(‐1) x min(‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline 0.9% (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 12270254

Group type: EXPERIMENTAL
Intervention: Large porous particles with MMAD approximately equal to 3 microm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large porous particles with MMAD approximately equal to 5 microm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AIR delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dry powder inhalers (DPI)
Number of subjects: 0
Study: 10396719

Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated whole blood
Number of subjects: 20
Study: 8579978

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2290270

Group type: EXPERIMENTAL
Intervention: Conventional IMN tablets (Monisid, Bulgaria)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-acting IMN tablets (Olicard, FRG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 20
Study: 7338570

Group type: EXPERIMENTAL
Intervention: Bumetanide (various doses in study 1 and 1 or 2 mg in study 2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Furosemide (40 or 80 mg in study 2)
Number of subjects: 56
Study: 30621211

Group type: EXPERIMENTAL
Intervention: Fermented Milk Product (FMP) containing Bifidobacterium animalis subsp. lactis CNCM I‐2494
Number of subjects: 538
Study: 29880794

Group type: EXPERIMENTAL
Intervention: Maternal iron deficiency (ID)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Non-iron deficient (non-ID) mothers
Number of subjects: 751

Group type: COMPARATOR
Intervention: Control group (placebo arm)
Number of subjects: 751
Study: 27438319

Group type: EXPERIMENTAL
Intervention: 90 mg of ticagrelor twice daily
Number of subjects: 21162

Group type: EXPERIMENTAL
Intervention: 60 mg of ticagrelor twice daily
Number of subjects: 21162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study: 25196041

Group type: EXPERIMENTAL
Intervention: 6 mg of nicotine gum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21896498

Group type: COMPARATOR
Intervention: Prescribed effluent rate of 20 mL/kg/h (standard dose)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prescribed effluent rate of 35 mL/kg/h (high dose)
Number of subjects: 200
Study: 19126058

Group type: EXPERIMENTAL
Intervention: 1% pyrithione zinc (PTZ) shampoo
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: 2% pyrithione zinc (PTZ) shampoo
Number of subjects: 722

Group type: COMPARATOR
Intervention: Matched placebo control shampoo
Number of subjects: 722
Study: 16797823

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Laparoscopy (subgroup with cysts > 7 cm)
Number of subjects: 127
Study: 16832816

Group type: EXPERIMENTAL
Intervention: Bortezomib at doses of 1.0 mg/m2, 1.3 mg/m2, or 1.5 mg/m2 on Days 1, 4, 8, and 11 of a 21-day treatment cycle for a maximum of 9 cycles
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.5 mg/m2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib (all doses)
Number of subjects: 22
Study: 12516653

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study: 10208253

Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet (70% CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) diet (40% CHO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High CHO diet
Number of subjects: 12
Study: 7628204

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine with sodium bicarbonate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 46
Study: 2692653

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 5 mg/kg/day for six days, first dose given immediately after mastectomy.
Number of subjects: 1026

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group).
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 5 mg/kg/day for six days, given 2-4 weeks after mastectomy (in a parallel study with 110 patients).
Number of subjects: 1026
Study: 786428

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 31422028

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 664

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 664
Study: 29120206

Group type: EXPERIMENTAL
Intervention: Mindfulness plus present control intervention
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Mindfulness only intervention
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Stress management information condition (active comparison)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Mindfulness plus present control and stress management conditions
Number of subjects: 365
Study: 26491824

Group type: EXPERIMENTAL
Intervention: 1 g myo‐inositol, 5 mg monacolin K, 400 mg lipoic acid for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 g myo‐inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months
Number of subjects: 30
Study: 23258817

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with redundant notifications
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with single transmissions
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM)
Number of subjects: 908
Study: 21500907

Group type: EXPERIMENTAL
Intervention: Practicing positive activities (expressing optimism and gratitude)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18325853

Group type: EXPERIMENTAL
Intervention: Brief intervention (all patients received this); patient satisfaction ratings >or=3.7 on 4-point scale.
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Intensive sexual risk reduction workshop (attended by 56% of invited patients); satisfaction ratings >or=3.6 on 4-point scale.
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3, 6, and 12 months.
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Behavior change and incident STIs assessed through ACASIs and urine specimens.
Number of subjects: 1483
Study: 16627865

Group type: EXPERIMENTAL
Intervention: Fluorescein-enhanced autofluorescence thoracoscopy (FEAT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: White light thoracoscopy (WLT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 29
Study: 14520767

Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline injected into the anterior temporalis muscle
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline injected into the masseter, lateral pterygoid, medial pterygoid, and anterior digastric muscles
Number of subjects: 15
Study: 11576047

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: 1% mepivacaine
Number of subjects: 58
Study: 9512261

Group type: EXPERIMENTAL
Intervention: Double test (free beta-HCG and alpha-fetoprotein)
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Triple tests (total HCG, alpha-fetoprotein, unconjugated oestriol)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Triple tests (free beta-HCG, alpha-fetoprotein, unconjugated oestriol)
Number of subjects: 2539
Study: 7519976

Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg per dose, 10 or 11 doses at 30 min intervals (total dose range 233-408 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cocaine days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 20
Study: 2846113

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment), first dose given the evening before surgery, further doses every evening thereafter.
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 1002
Study: 1149632

Group type: EXPERIMENTAL
Intervention: Factor VIII concentrates (n=8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Infusion treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of haemostatic and anti-inflammatory substances, physiotherapy, and orthopaedic means
Number of subjects: 15
Study: 31105703

Group type: EXPERIMENTAL
Intervention: Golimumab (GM) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: GM untreated group
Number of subjects: 0
Study: 27853886

Group type: EXPERIMENTAL
Intervention: Home-based isometric exercise training (IET)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 25969139

Group type: EXPERIMENTAL
Intervention: Melatonin (3+3mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 23171351

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 100
Study: 21762532

Group type: EXPERIMENTAL
Intervention: Multimodal smoking cessation intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hospital smoking care only
Number of subjects: 200
Study: 19226238

Group type: EXPERIMENTAL
Intervention: Passive joint mobilisation of shoulder region joints
Number of subjects: 90

Group type: COMPARATOR
Intervention: Advice and exercise alone
Number of subjects: 90
Study: 17118828

Group type: EXPERIMENTAL
Intervention: Topical cooling with ice‐slush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crystalloid antegrade cardioplegia
Number of subjects: 60
Study: 15302008

Group type: EXPERIMENTAL
Intervention: Tezosentan 5 mg/h
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Tezosentan 25 mg/h
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Tezosentan 1 mg/h
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Tezosentan 0.2 mg/h
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 11762740

Group type: EXPERIMENTAL
Intervention: Milk-based dietary supplements (powder reconstituted in fat-free milk)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ready-to-drink milk-based supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-lactose control preparations
Number of subjects: 10
Study: 9420452

Group type: EXPERIMENTAL
Intervention: Low-dose micronutrient supplement containing trace minerals (zinc and selenium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamins/provitamins (vitamin C, alpha-tocopherol, and beta-carotene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29483583

Group type: COMPARATOR
Intervention: TE regimen (docetaxel and epirubicin)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: TEL regimen (docetaxel, epirubicin, and lobaplatin)
Number of subjects: 125
Study: 27433815

Group type: EXPERIMENTAL
Intervention: Cyclosporine (2.5 mg/kg intravenous bolus at the onset of advanced cardiovascular life support)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 794

Group type: COMPARATOR
Intervention: Control
Number of subjects: 794
Study: 23670810

Group type: EXPERIMENTAL
Intervention: Aboulker stent (A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Silastic stent (S)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Type of stent used
Number of subjects: 24